Table 2 HRs for overall survival by subgroup
Groups | OS | P | cHR | 95% CI | aHR | 95% CI | |||
|---|---|---|---|---|---|---|---|---|---|
Age | > 45 | 71 | 1.000 | 1.000 | |||||
≤ 45 | – | 0.022 | 0.349 | 0.142 | 0.859 | 0.246 | 0.098 | 0.621 | |
Gender | Male | 68 | 1.000 | ||||||
Female | 92 | 0.400 | 1.087 | 0.895 | 1.320 | ||||
Smoking | No | 76 | 1.000 | ||||||
Yes | 72 | 0.968 | 1.009 | 0.647 | 1.574 | ||||
Family history | No | 71 | 1.000 | ||||||
Yes | 83 | 0.350 | 0.750 | 0.410 | 1.372 | ||||
Disease history | No | 72 | 1.000 | ||||||
Yes | – | 0.724 | 0.777 | 0.191 | 3.161 | ||||
Histopathologic type | AD | 76 | 1.000 | 1.000 | |||||
Non AD | 53 | 0.027 | 2.260 | 1.097 | 4.659 | 3.279 | 1.558 | 6.900 | |
Differentiation | High | 72 | 1.000 | ||||||
Middle | 68 | 0.300 | 1.484 | 0.703 | 3.131 | ||||
Low | – | 0.320 | 1.325 | 0.746 | 2.452 | ||||
Stage | I | 83 | 1.000 | 1.000 | |||||
II | 68 | 0.209 | 1.507 | 0.795 | 2.857 | 1.455 | 0.751 | 2.282 | |
III | – | 0.037 | 1.706 | 1.032 | 2.821 | 1.621 | 0.968 | 2.715 | |
IV | 65 | 0.095 | 1.750 | 0.908 | 3.372 | 1.748 | 0.905 | 3.337 | |
Operation | Radical | 68 | |||||||
Palliative | 72 | 0.762 | 1.086 | 0.637 | 1.852 | ||||
Adjuvant chemotherapy | No | 76 | 1.000 | ||||||
Yes | 67 | 0.688 | 0.904 | 0.554 | 1.477 | ||||
Adjuvant radiation | No | 81 | 1.000 | ||||||
Yes | 68 | 1.356 | 1.356 | 0.917 | 2.006 | ||||
TKI | Gefitinib | 72 | 1.000 | 1.000 | |||||
Erlotinib Hydrochloride | 68 | 0.889 | 1.038 | 0.613 | 1.759 | 0.956 | 0.562 | 1.627 | |
Icotinib | – | 0.022 | 0.379 | 0.165 | 0.871 | 0.316 | 0.137 | 0.731 | |
Others | 45 | 0.183 | 1.761 | 0.765 | 4.054 | 1.433 | 0.618 | 3.327 | |
EGFR mutation | 19 del | 92 | 1.000 | 1.000 | |||||
21 L858R | 65 | 0.018 | 1.265 | 1.041 | 1.538 | 1.275 | 1.040 | 1.563 | |